IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a report issued on Saturday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

Shares of IRIDEX stock opened at $1.77 on Friday. The stock has a market capitalization of $29.45 million, a price-to-earnings ratio of -2.64 and a beta of 0.82. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. The business has a 50-day moving average of $1.68 and a 200 day moving average of $1.83.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The company had revenue of $11.58 million during the quarter. During the same period in the previous year, the firm earned ($0.11) EPS.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.